14 Apr 2021
Posted in Pharma
Diagnosed prevalent cases of Parkinson’s disease to reach 3 million by 2029 in the 7MM, says GlobalData
The number of diagnosed prevalent cases of Parkinson’s disease is expected to rise in the seven major markets (7MM), which comprises the US, France, Germany, Italy, Spain, the UK and Japan. Out of these countries, leading data and analytics company GlobalData notes that the US will have the highest number of cases in 2029 at 782,000, whereas the UK will see 111,000 cases, the lowest in the 7MM.
GlobalData’s latest report, ‘Parkinson’s Disease – Epidemiology Forecast to 2029’, notes that Parkinson’s disease cases are projected to increase from 2.4 million in 2019 to three million in 2029, equating an annual growth rate (AGR) of 2.32%. Men and women were found to make up an equal proportion of the diagnosed prevalent cases of PD in the 7MM combined – although there are variations in the predominant sex by market.
Bharti Prabhakar, MPH, Senior Epidemiologist at GlobalData, explains: “Although PD prevalence was higher in men in the 7MM, the number of actual prevalent cases was higher in women – as the population of elderly women was higher than elderly men. However, diagnosed prevalence of PD is higher in women than men in Japan. An environmental or genetic factor significantly associated with men in Europe and the US and women in Japan could pose a risk for PD.”
PD is one of the most common chronic progressive neurodegenerative disorders in the elderly population. As PD predominantly affects older adults, countries with growing aging populations increasingly need to develop strategies to meet the healthcare needs of individuals with PD.
** 7MM: The US, 5EU (France, Germany, Italy, Spain, UK), and Japan